Karin Granath appointed new CEO of PeptiSystems
PeptiSystems announces that Karin Granath has joined on June 3rd, 2023, to take over the role of PeptiSystems CEO. PeptiSystems is currently in an expansion phase after having a very successful first year of sales of both peptide and oligonucleotide synthesis instruments since the launch of the products in Q1 2022.
Karin has over 20 years of experience in different leadership positions within the MedTech industry, and she is most recently joining from GE Healthcare, where she had a position as General Manager for a subdivision in the Molecular Imaging space.
Karin Granath comments, “I am very excited to have joined PeptiSystems and look forward to leading the company on our continued expansion journey. I am impressed how PeptiSystems has transferred their deep knowledge in oligonucleotide synthesis to also successfully apply the solid-phase flow through column technology to peptide manufacturing processing.“
With 40 years in the field, Lars Holmberg will transition to the Chief Scientific Officer role and focus mainly on product development activities. “I am happy to have Karin onboard to drive the business expansion. This enables me to focus on the important technical aspects of our product portfolio.”
Mats Johnson, Chairman of the Board: “Together with his colleagues, Lars has done an excellent job building a profitable company in the first year of sales. Karin will now use her experience to build the company further. We expect continued fast growth in the next three years.“
For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
Email: karin.granath@peptisystems.com
About PeptiSystems AB
PeptiSystems is a biotech company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilizing proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.